DWA
CATX icon

Douglass Winthrop Advisors’s Perspective Therapeutics CATX Stock Holding History

Douglass Winthrop Advisors’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,000
Closed -$4K – 259
2022
Q1 		$4K Buy
+1,000
New +$3.65K ﹤0.01% 267

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TMWM
Taylor & Morgan Wealth Management Flint, Michigan $203M AUM 24.74% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Venator Capital Management Toronto, Ontario, Canada $48.7M AUM 87.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Douglass Winthrop Advisors's CATX Position: Q2 2022 in Review

Douglass Winthrop Advisors sold out of Perspective Therapeutics (CATX) in Q2 2022, closing a stake of 1,000 shares — an estimated $4K sold.

Douglass Winthrop Advisors first reported a position in CATX in Q1 2022 and held it in 1 quarter. The position peaked at $4K in Q1 2022. 43 funds tracked by Wall St. Rank hold CATX as of Q2 2022.

  • Douglass Winthrop Advisors reported no remaining Perspective Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Douglass Winthrop Advisors sold 1,000 Perspective Therapeutics shares in Q2 2022, an estimated $4K.
  • Douglass Winthrop Advisors first reported a position in Perspective Therapeutics in Q1 2022 and held it in 1 quarter.
  • Douglass Winthrop Advisors's Perspective Therapeutics position peaked at $4K in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2022.

Based on Douglass Winthrop Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.